http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007117653-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0c634c40dd6ad85e2dd3efadea802b18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24947f43c2ad4e919d2319cd52817aac http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-452 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-452 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate | 2007-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8840f709665b9b21c068ecad45750d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4904650435f46693525771654ce5c04c |
| publicationDate | 2007-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007117653-A2 |
| titleOfInvention | Cdk9-pi3k-akt inhibitors for cancer treatment |
| abstract | A combination therapy treatment for cancer is disclosed using an inhibitor of the PI3K/Akt pathway and roscovitine. It is shown that combinations of roscovitine with API-2 or LY294002 induce apoptosis of androgen-dependeπt (LNCaP) and androgen-independent (PC3) prostate cancer cells. Cells that respond to roscovitine alone (LNCaP) initiate apoptosis sooner when co-treated. Cells that do not respond to roscovitine alone (PC3) apoptose when co-treated, although with delayed kinetics. Without roscovitine, AKT inhibitors had no effect on LNCaP or PC3 survival, while combined treatment activated the mitochondrial pathway of apoptosis. Normal epithelial cells (RPWE) remained viable in the presence of roscovitine and AKT inhibitors. Events elicited by roscovitine (down-regulation of XlAP) and AKT inhibitors (accumulation of Bim) in LNCaP and PC3 cells are identified. PC3 cells treated with AKT inhibitors and depleted of either XlAP or Cdk9 apoptose. These results suggest improved treatments for cancers through the combination therapies taught herein. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10639302-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9498471-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10172844-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11020404-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10300073-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11351161-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016061144-A1 |
| priorityDate | 2006-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 480.